NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Annovis Bio Inc. (NYSE: ANVS) announces the availability of a broadcast titled, “Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition.”To hear the AudioPressRelease, please visit: The NetworkNewsAudioTo view the full editorial, please visit: https://nnw.fm/ZIUidAnnovis Bio Inc.

2024年10月3日，纽约（环球通讯社）--NetworkNewsAudio–Annovis Bio Inc.（纽约证券交易所：ANVS）宣布推出名为“改变阿尔茨海默氏病治疗：创新组合以提高认知能力”的广播。要收听音频新闻稿，请访问：NetworkNewsAudio要查看完整的社论，请访问：https://nnw.fm/ZIUidAnnovis生物公司。

is at the forefront of the movement to develop new safe and effective drugs for neurodegenerative diseases, including AD. The company has long pursued the goal to improve the health of nerve cells and, in the process, improve cognition in neurodegenerative disorders. The company’s lead drug candidate, buntanetap, has completed late-stage AD and PD clinical trials and was shown to be efficacious in both indications.

是开发新的安全有效的神经退行性疾病药物（包括AD）运动的前沿。该公司长期以来一直追求改善神经细胞健康的目标，并在此过程中提高对神经退行性疾病的认知。该公司的主要候选药物buntanetap已完成晚期AD和PD临床试验，并被证明对这两种适应症均有效。

Earlier this year, Annovis announced promising results from its phase 2/3 clinical trial of buntanetap as an oral therapy for early AD. The study involved 353 patients and assessed buntanetap’s efficacy on top of standard of care medications as well as its safety.About Annovis Bio Inc. Annovis Bio, headquartered in Malvern, Pennsylvania, is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”).

今年早些时候，Annovis宣布了布坦塔普作为早期AD口服疗法的2/3期临床试验的有希望的结果。该研究涉及353名患者，并评估了布坦塔普在标准护理药物上的疗效及其安全性。关于Annovis Bio Inc.总部位于宾夕法尼亚州马尔文的Annovis Bio致力于解决阿尔茨海默氏病（“AD”）和帕金森氏病（“PD”）等疾病中的神经退行性疾病。

The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, about the company, please visit www.AnnovisBio.com.NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS http://nnw.fm/ANVSAbout NetworkNewsWireNetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and.

该公司的创新方法针对多种神经毒性蛋白质，旨在恢复大脑功能并改善患者的生活质量。有关该公司的更多信息，请访问www.AnnovisBio.com.NOTE TO INVESTORS：有关ANV的最新新闻和更新，请访问该公司的新闻编辑室https://ibn.fm/ANVS（笑声）http://nnw.fm/ANVSAboutNetworkNewsWireNetworkNewsWire（“NNW”）是一个专门的通信平台，专注于为私营和上市公司提供金融新闻和内容分发。